Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.55 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | KLK7 | P49862 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL482453 | 0.89 | L3MBTL1 (0.69) | SMN1; SMN2LMNAMEN1KMT2AL3MBTL1 | |
| SCHEMBL3147011 | 0.79 | MEN1 (0.57) | SMN1; SMN2LMNAMEN1KMT2ASAE1 | |
| SCHEMBL30034264 | 0.78 | SMN1; SMN2 (0.88) | SMN1; SMN2LMNAMEN1KMT2AL3MBTL1 | |
| SCHEMBL9313874 | 0.77 | L3MBTL1 (0.76) | SMN1; SMN2LMNAMEN1KMT2AL3MBTL1 | |
| SCHEMBL121529 | 0.77 | CHRM2 (0.70) | SMN1; SMN2ALDH1A1HTTKDM4EPOLB | |
| SCHEMBL17916794 | 0.75 | SMN1; SMN2 (0.88) | SMN1; SMN2MEN1KMT2AL3MBTL1SAE1 | |
| Hydrochloric Acid SCHEMBL2147064 | 0.75 | CHRM2 (0.68) | SMN1; SMN2ALDH1A1RAB9AHTTKDM4E | |
| Hydrochloric Acid SCHEMBL9479560 | 0.75 | CHRM2 (0.68) | SMN1; SMN2ALDH1A1RAB9AHTTKDM4E | |
| SCHEMBL2089592 | 0.74 | L3MBTL1 (0.71) | SMN1; SMN2LMNAMEN1KMT2AL3MBTL1 | |
| SCHEMBL2954416 | 0.74 | L3MBTL1 (0.71) | SMN1; SMN2LMNAMEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329911-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-7642355-B2 | Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-(2-(5-[4-(3-dimethylaminopropoxy)benzylamino]pentylcarbamoyl)ethyl)piperidin-4-yl ester | THERAVANCE, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20060205779-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205779-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | SMN1; SMN2 4327/4885LMNA 2089/4885MEN1 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.